Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Polycystic Ovarian Syndrome
NCT06222437Phase 1Withdrawn
- Sponsor
- Methodist Health System
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in polycystic ovary syndrome (PCOS), sponsored by Methodist Health System. Primary endpoints: Number of appropriate weekly dose at 4 weeks and Number of days on therapy at 4 weeks. Planned start Feb 2026; status: withdrawn.
02
Drugs
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT06222437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222437.